Key Events This Week
20 Jul: Stock opens at Rs.1,956.30, gaining 1.20%
21 Jul: New 52-week and all-time high at Rs.1,966.75 / Rs.1,963.30
23 Jul: Valuation shift noted; stock closes at Rs.1,942.95 (-0.98%)
24 Jul: Week closes at Rs.1,941.00 (-0.67%)
Monday, 20 July 2026: Strong Start Despite Flat Sensex
Sun Pharma began the week on a positive note, closing at Rs.1,956.30, up Rs.23.20 or 1.20% from the previous Friday’s close of Rs.1,933.10. This gain came despite the Sensex remaining virtually flat, down 0.00% at 36,504.94. The stock’s volume was moderate at 56,408 shares, indicating steady investor interest. This early strength set the tone for the week’s momentum.
Tuesday, 21 July 2026: New 52-Week and All-Time Highs Amid Market Weakness
On 21 July, Sun Pharmaceutical Industries Ltd achieved a significant milestone by hitting a new 52-week high of Rs.1,966.75 and an all-time high of Rs.1,963.30 during the trading session. The stock closed at Rs.1,962.15, up Rs.5.85 or 0.30% on the day, extending gains from the previous session. This performance was remarkable given the Sensex declined by 0.88% to 36,196.43, reflecting the stock’s relative strength within a weakening market.
The stock’s technical positioning was robust, trading comfortably above all key moving averages, signalling sustained buying interest. Institutional investors’ confidence remained strong, with a 36.71% stake backing the company. Despite a premium valuation with a P/E ratio near 38x and a PEG ratio above 4.0, the stock’s fundamentals, including net-debt-free status and healthy sales growth, supported this elevated pricing.
Our latest weekly pick is out! This Large Cap from Steel/Sponge Iron/Pig Iron delivered with target price and complete analysis. See what makes this week's selection special!
- - Latest weekly selection
- - Target price delivered
- - Large Cap special pick
Wednesday, 22 July 2026: Profit Taking Amid Broader Market Sell-Off
The stock corrected on 22 July, closing at Rs.1,942.95, down Rs.19.20 or 0.98%. This decline coincided with a sharp Sensex drop of 0.88% to 36,196.43, reflecting broader market weakness. Volume was relatively low at 64,866 shares, suggesting selective profit booking rather than widespread selling pressure. The stock remained near its 52-week high, indicating that the correction was a short-term pause rather than a reversal of the uptrend.
Thursday, 23 July 2026: Valuation Shift Signals Renewed Price Attractiveness
On 23 July, Sun Pharma’s valuation parameters underwent a notable recalibration. The stock’s price-to-earnings ratio moderated slightly to 37.39 from previous levels, moving the rating from 'very expensive' to 'expensive'. The price-to-book value stood at 5.58, consistent with a premium large-cap stock but signalling a slight easing in valuation pressure.
The stock closed at Rs.1,942.95, down 0.98% on the day, while the Sensex declined 0.70% to 35,944.66. This valuation adjustment was accompanied by a Mojo Grade upgrade to Buy with a Mojo Score of 74.0, reflecting improved market sentiment and a more balanced risk-reward profile. Compared to peers such as Divi’s Laboratories and Torrent Pharmaceuticals, Sun Pharma’s valuation appeared more reasonable, supporting its leadership position in the Pharmaceuticals & Biotechnology sector.
Friday, 24 July 2026: Week Ends with Minor Decline Amid Market Pressure
The week concluded with Sun Pharma closing at Rs.1,941.00, down Rs.13.05 or 0.67% from the previous day’s close. The Sensex also declined by 0.32% to 35,829.46, continuing the broader market’s downward trend. Volume was moderate at 201,886 shares, indicating steady trading activity. Despite the minor pullback, the stock ended the week with a net gain of 0.41%, significantly outperforming the Sensex’s 1.85% loss.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-07-20 | Rs.1,956.30 | +1.20% | 36,504.94 | -0.00% |
| 2026-07-21 | Rs.1,962.15 | +0.30% | 36,518.28 | +0.04% |
| 2026-07-22 | Rs.1,942.95 | -0.98% | 36,196.43 | -0.88% |
| 2026-07-23 | Rs.1,954.05 | +0.57% | 35,944.66 | -0.70% |
| 2026-07-24 | Rs.1,941.00 | -0.67% | 35,829.46 | -0.32% |
Want to dive deeper on Sun Pharmaceutical Industries Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Key Takeaways
Outperformance Amid Market Weakness: Sun Pharma’s 0.41% weekly gain contrasted with the Sensex’s 1.85% decline, highlighting the stock’s defensive qualities and sector leadership.
Technical Strength and Milestones: The stock’s new 52-week and all-time highs on 21 July demonstrated strong technical momentum, supported by bullish indicators such as MACD and Bollinger Bands on weekly and monthly charts.
Valuation Moderation: The shift from a 'very expensive' to 'expensive' valuation rating, alongside a Mojo Grade upgrade to Buy, suggests improved price attractiveness despite premium multiples. This adjustment aligns Sun Pharma’s valuation more closely with peers while maintaining its growth premium.
Financial Fundamentals: The company’s net-debt-free status, robust return on equity (15.58%), and consistent sales growth underpin its market position. However, recent quarterly profit declines indicate a flat short-term earnings trend that investors should monitor.
Institutional Confidence: A significant 36.71% institutional holding reflects strong backing from long-term investors, reinforcing the stock’s stability and quality credentials.
Conclusion
Sun Pharmaceutical Industries Ltd demonstrated resilience and relative strength during a challenging week for the broader market. The stock’s ability to reach new highs and maintain gains amid Sensex declines underscores its leadership in the Pharmaceuticals & Biotechnology sector. While valuation remains elevated, the recent moderation and upgrade in Mojo Grade to Buy signal a more balanced risk-reward profile. Investors should weigh the company’s strong fundamentals and technical momentum against the flat short-term earnings trend. Overall, Sun Pharma remains a key large-cap stock exhibiting defensive qualities and sustained growth potential within its sector.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
